An Observational Study to Assess Nirsevimab Immunization Rates in Eligible Infants During Their First RSV Season in the Czechia

NCT07634692 · clinicaltrials.gov ↗

COMPLETED

Status

257

Enrollment

INDUSTRY

Sponsor class

Conditions

RSV Immunization

Interventions

BIOLOGICAL: Nirsevimab Respiratory Syncytial Virus monoclonal antibody

Sponsor

Sanofi